S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

$1.80
-0.02 (-1.10%)
(As of 12:06 PM ET)
Today's Range
$1.78
$1.85
50-Day Range
$1.78
$2.53
52-Week Range
$0.90
$3.49
Volume
95,428 shs
Average Volume
213,406 shs
Market Capitalization
$70.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Cognition Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
312.1% Upside
$7.50 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of Cognition Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$9,975 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.10) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

377th out of 939 stocks

Biological Products, Except Diagnostic Industry

55th out of 156 stocks

CGTX stock logo

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CGTX Stock Price History

CGTX Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
A Preview Of Cognition Therapeutics's Earnings
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Cognition Therapeutics Inc CGTX
See More Headlines
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGTX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$9.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+312.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.39 per share

Miscellaneous

Free Float
29,718,000
Market Cap
$70.98 million
Optionable
Not Optionable
Beta
1.67
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

CGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings
or view top-rated stocks.

What is Cognition Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12-month target prices for Cognition Therapeutics' stock. Their CGTX share price targets range from $6.00 to $9.00. On average, they expect the company's share price to reach $7.50 in the next year. This suggests a possible upside of 312.1% from the stock's current price.
View analysts price targets for CGTX
or view top-rated stocks among Wall Street analysts.

How have CGTX shares performed in 2024?

Cognition Therapeutics' stock was trading at $1.85 on January 1st, 2024. Since then, CGTX stock has decreased by 1.6% and is now trading at $1.82.
View the best growth stocks for 2024 here
.

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CGTX earnings forecast
.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) posted its earnings results on Tuesday, November, 16th. The company reported ($8.12) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $7.55.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pathstone Holdings LLC (6.87%), Vanguard Group Inc. (2.25%), Vanguard Group Inc. (2.25%), Kestra Advisory Services LLC (0.68%), Mercer Global Advisors Inc. ADV (0.41%) and Twin Focus Capital Partners LLC (0.29%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace.
View institutional ownership trends
.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners